Fifty years of experience with antithrombotic therapy in cardiac disease. A 1996 approach based on pathogenesis and risk.
Freudenberger
R S
RS
Fuster
V
V
D000925:Anticoagulants / Q000627:therapeutic use*; D000991:Antithrombins / Q000627:therapeutic use*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D017202:Myocardial Ischemia / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D013927:Thrombosis / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control
D000925:Anticoagulants; D000991:Antithrombins; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors